Ifetroban

Phase 2Small molecule

CCumberland Pharmaceuticals

Ifetroban is one of 115 small molecule programs targeting Portal Hypertension. It is currently in Phase 2.

Indications

Total Trials

Active Trials

114

Competitors

Pipeline

Status by Indication[3][1]

Indication

Portal HypertensionActive, not recruiting

Hepatorenal SyndromeActive, not recruiting

Pulmonary Arterial HypertensionActive, not recruiting

Duchenne Muscular DystrophyActive, not recruiting

Portal HypertensionPhase 2

Active, not recruiting

Hepatorenal SyndromePhase 2

Active, not recruiting

Pulmonary Arterial HypertensionPhase 2

Active, not recruiting

Duchenne Muscular DystrophyPhase 2

Active, not recruiting

Competition

Competitive Landscape

179 competitors in Pulmonary Arterial Hypertension

#DrugCompanyPhaseTrials

Gleevec

Novartis

Phase 3

6 2

Reata

Biogen

Phase 3

1 3

Levitra

Bayer

Phase 3

1 4

Aurlumyn

BBTG International Inc.

Phase 3

8 5

Flolan

Johnson & Johnson

Phase 3

1 6

Zesly

MMezzion Pharma Co. Ltd

Phase 3

1 7

Atrovent

Inhaled Iloprost

1 9

Farxiga

AstraZeneca

Phase 2

1 10

Nolvadex

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Respiratory Disease3 trials

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban

Completed·—·Phase 2·NCT03326063·38 enrolled

Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease

Completed·CCumberland Pharmaceuticals·Phase 2·NCT02216357·19 enrolled

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)

Completed·CCumberland Pharmaceuticals·Phase 2·NCT03028350·54 enrolled

Duchenne Muscular Dystrophy1 trial

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

Completed·CCumberland Pharmaceuticals·Phase 2·NCT03340675·46 enrolled

Portal Hypertension1 trial

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients

Completed·CCumberland Pharmaceuticals·Phase 2·NCT02802228·30 enrolled

Pulmonary Arterial Hypertension1 trial

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Active, not recruiting·CCumberland Pharmaceuticals·Phase 2·NCT02682511·34 enrolled

Hepatorenal Syndrome1 trial

Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

Completed·CCumberland Pharmaceuticals·Phase 2·NCT01436500·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Ifetroban. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ifetroban compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ifetroban. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cumberland Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCumberland Pharmaceuticals

Ifetroban

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Respiratory Disease3 trials

Duchenne Muscular Dystrophy1 trial

Portal Hypertension1 trial

Pulmonary Arterial Hypertension1 trial

Hepatorenal Syndrome1 trial

References

Drug Info

Quick Facts

Related News